肿瘤细胞治疗研究
英文原题：Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.
Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.
本研究表明，无论移植前疾病状态如何均能获益，这对HCT需要缓解的要求提出了挑战。
异基因造血细胞移植（HCT）是外周T/NK细胞淋巴瘤（PTCL）患者的潜在治愈手段，但其应用研究不足。这项前瞻性试验在31例PTCL患者中评估了一种独特的减低强度（RIC）移植方案（NCT03922724）。主要终点1年无进展生存率在RIC组为53%（95% CI 29-72%），在改良RIC组为60%（95% CI 25-83%）。3年总生存率为61%（95% CI 42-76%），3年复发率估计为18%（95% CI 6-34%）。1年移植相关死亡率为24%（95% CI 10-41%），60岁患者较低，为11%（95% CI 2-29%），而>60岁患者为56%（95% CI 17-82%），p = 0.01。未发生III-IV级急性移植物抗宿主病，而2年慢性移植物抗宿主病估计为23%（95 CI 10-38%）。这项研究表明，无论移植前疾病状态如何均可获益，挑战了HCT需要达到缓解的要求。
Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients 60 years but 56% (95% CI 17-82%) for patients >60 years, p = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.
MEMBER ACCOUNT
登录成功会直接打开下一页。
